We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is it a Prudent Move to Retain ALC Stock in Your Portfolio Now?
Read MoreHide Full Article
Key Takeaways
Alcon is expanding across surgery, diagnostics and ocular health through deals and partnerships.
ALC's new equipment, lenses and eye-care products are expected to support growth in upcoming quarters.
Alcon faces tariff uncertainty, uneven procedure trends and intense competition across key markets.
Alcon’s (ALC - Free Report) platform expansion through investments, acquisitions and partnerships is likely to support growth in the upcoming quarters. The company’s new platforms and lenses are also gaining adoption. However, challenging tariff conditions and intense competition may adversely impact its operations.
In the past year, this Zacks Rank #3 (Hold) stock has dipped 8.4% compared with the industry’s 2.5% decline. The S&P 500 composite has risen 20.3% in the same time frame.
The renowned pharmaceutical and medical device manufacturer has a market capitalization of $32.77 billion. ALC’s earnings surpassed estimates in three of the trailing four quarters and missed in one, delivering an average surprise of 4.2%.
Let’s delve deeper.
Upsides for ALC
Business Development Activities: Alcon continues to expand its platform across surgery, diagnostics and ocular health by adding external technologies. Its 2025 majority investment in Aurion Biotech added AURN001 to its pipeline, while the acquisitions of LumiThera and Cylite brought Valeda for early and intermediate dry age-related macular degeneration and Hyperparallel Optical Coherence Tomography technology for cataract diagnostics, respectively.
In the second quarter of 2026, Valeda adoption increased as the installed base and utilization rose, and management said the platform could generate $100 million to $150 million of sales over a three-to-five-year period. Alcon also announced a collaboration with RxSight to combine advanced optics and lens architecture with an adjustability platform. These additions extend the company’s development options beyond internal R&D while supporting participation across multiple eye-care categories.
New Products Strengthen Growth Prospects: Alcon’s growth strategy remains tied to a broad launch cadence across equipment, IOLs, dry eye and contact lenses. Unity VCS and Unity CS continue to lead the current equipment cycle, while the company made its first sale of the Unity M microscope in the second quarter of 2026.
PanOptix Pro is now rolling out internationally following rapid adoption in the United States while TruPlus has entered a KOL launch in the country after receiving CE Mark approval in Europe. Vivity Pro has been submitted in both the United States and Europe, with management expecting a key opinion leader (KOL) launch late in 2026 or early 2027. Unity DX is expected to enter pilot use later in 2026, with revenues anticipated around mid-2027. Tryptyr, Valeda, PanOptix Pro in Europe and Unity CS are expected to contribute more in the second half.
Image Source: Zacks Investment Research
What Ails ALC Stock?
Trade and Demand Risks Persist: Alcon remains exposed to tariff changes and uneven procedure trends that can raise costs and reduce operating leverage. In the second quarter of 2026, the company assumed U.S. import tariff rates of about 10% to 12.5% would remain in effect through year-end.
Guidance also includes an anticipated third-quarter tariff refund of about $60 million, with roughly two-thirds expected to be reinvested in the business. Although cataract demand improved sequentially, U.S. procedure volumes remained flat, while global volumes grew only in the low single digits. These conditions leave earnings sensitive to trade policy and procedure growth, even as new product launches support sales.
Tough Competitive Landscape: Competition remains intense across both segments, particularly as Alcon defends its market share outside the United States and navigates mix transitions.
The category also remains highly competitive, with newer entrants targeting value tiers while the market continues to shift toward daily lenses and advanced materials. These dynamics increase the company’s reliance on newer platforms to sustain growth, requiring continued investment in commercialization and physician education to preserve pricing power and market positioning over time.
ALC Stock Estimate Trend
The Zacks Consensus Estimate for 2026 earnings per share has moved south to $3.48 in the past 30 days.
The Zacks Consensus Estimate for 2026 revenues is pegged at $11.11 billion, suggesting a 7.7% rise from the year-ago reported number.
Globus Medical has an earnings yield of 5.8% against the industry’s negative 1.7% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 27.9%. GMED’s shares have rallied 42.3% against the industry’s 6.3% decline over the past year.
Veracyte, sporting a Zacks Rank #1 at present, has an earnings yield of 4.6% against the industry’s negative 1.7% yield. Shares of the company have risen 38% against the industry’s 6.3% decline. VCYT’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 41.8%.
Illumina, presently carrying a Zacks Rank #2 (Buy), has an estimated long-term earnings growth rate of 13% compared with the industry’s 23% growth. Its earnings beat estimates in each of the trailing four quarters, the average surprise being 9.7%. ILMN’s shares have rallied 194.6% compared with the industry’s 24.6% growth over the past year.
View the Zacks #1 Rank List
Image: Bigstock
Is it a Prudent Move to Retain ALC Stock in Your Portfolio Now?
Key Takeaways
Alcon’s (ALC - Free Report) platform expansion through investments, acquisitions and partnerships is likely to support growth in the upcoming quarters. The company’s new platforms and lenses are also gaining adoption. However, challenging tariff conditions and intense competition may adversely impact its operations.
In the past year, this Zacks Rank #3 (Hold) stock has dipped 8.4% compared with the industry’s 2.5% decline. The S&P 500 composite has risen 20.3% in the same time frame.
The renowned pharmaceutical and medical device manufacturer has a market capitalization of $32.77 billion. ALC’s earnings surpassed estimates in three of the trailing four quarters and missed in one, delivering an average surprise of 4.2%.
Let’s delve deeper.
Upsides for ALC
Business Development Activities: Alcon continues to expand its platform across surgery, diagnostics and ocular health by adding external technologies. Its 2025 majority investment in Aurion Biotech added AURN001 to its pipeline, while the acquisitions of LumiThera and Cylite brought Valeda for early and intermediate dry age-related macular degeneration and Hyperparallel Optical Coherence Tomography technology for cataract diagnostics, respectively.
In the second quarter of 2026, Valeda adoption increased as the installed base and utilization rose, and management said the platform could generate $100 million to $150 million of sales over a three-to-five-year period. Alcon also announced a collaboration with RxSight to combine advanced optics and lens architecture with an adjustability platform. These additions extend the company’s development options beyond internal R&D while supporting participation across multiple eye-care categories.
New Products Strengthen Growth Prospects: Alcon’s growth strategy remains tied to a broad launch cadence across equipment, IOLs, dry eye and contact lenses. Unity VCS and Unity CS continue to lead the current equipment cycle, while the company made its first sale of the Unity M microscope in the second quarter of 2026.
PanOptix Pro is now rolling out internationally following rapid adoption in the United States while TruPlus has entered a KOL launch in the country after receiving CE Mark approval in Europe. Vivity Pro has been submitted in both the United States and Europe, with management expecting a key opinion leader (KOL) launch late in 2026 or early 2027. Unity DX is expected to enter pilot use later in 2026, with revenues anticipated around mid-2027. Tryptyr, Valeda, PanOptix Pro in Europe and Unity CS are expected to contribute more in the second half.
Image Source: Zacks Investment Research
What Ails ALC Stock?
Trade and Demand Risks Persist: Alcon remains exposed to tariff changes and uneven procedure trends that can raise costs and reduce operating leverage. In the second quarter of 2026, the company assumed U.S. import tariff rates of about 10% to 12.5% would remain in effect through year-end.
Guidance also includes an anticipated third-quarter tariff refund of about $60 million, with roughly two-thirds expected to be reinvested in the business. Although cataract demand improved sequentially, U.S. procedure volumes remained flat, while global volumes grew only in the low single digits. These conditions leave earnings sensitive to trade policy and procedure growth, even as new product launches support sales.
Tough Competitive Landscape: Competition remains intense across both segments, particularly as Alcon defends its market share outside the United States and navigates mix transitions.
The category also remains highly competitive, with newer entrants targeting value tiers while the market continues to shift toward daily lenses and advanced materials. These dynamics increase the company’s reliance on newer platforms to sustain growth, requiring continued investment in commercialization and physician education to preserve pricing power and market positioning over time.
ALC Stock Estimate Trend
The Zacks Consensus Estimate for 2026 earnings per share has moved south to $3.48 in the past 30 days.
The Zacks Consensus Estimate for 2026 revenues is pegged at $11.11 billion, suggesting a 7.7% rise from the year-ago reported number.
Key Picks
Some better-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Veracyte (VCYT - Free Report) and Illumina (ILMN - Free Report) .
Globus Medical has an earnings yield of 5.8% against the industry’s negative 1.7% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 27.9%. GMED’s shares have rallied 42.3% against the industry’s 6.3% decline over the past year.
GMED sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Veracyte, sporting a Zacks Rank #1 at present, has an earnings yield of 4.6% against the industry’s negative 1.7% yield. Shares of the company have risen 38% against the industry’s 6.3% decline. VCYT’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 41.8%.
Illumina, presently carrying a Zacks Rank #2 (Buy), has an estimated long-term earnings growth rate of 13% compared with the industry’s 23% growth. Its earnings beat estimates in each of the trailing four quarters, the average surprise being 9.7%. ILMN’s shares have rallied 194.6% compared with the industry’s 24.6% growth over the past year.